WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled a webcast for 8:30 p.m. CT / 9:30 p.m. ET on Monday, December 7, 2009 to discuss clinical results for its lead JAK 1/JAK 2 inhibitor, INCB18424, which will be the subject of three oral presentations at the 51st American Hematology Annual Meeting in New Orleans.
